Researchers will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is ...
Washington, DC and Glendale, CA - In the wake of postmarketing reports describing serious thrombotic events possibly associated with administration of immune globulin intravenous (IGIV), the American ...
Readers are referred to the cautionary note regarding Forward-looking Information at the end of this release. WINNIPEG, July 10, 2012 /CNW/ - Cangene Corporation (Cangene) today announces that ...
Researchers have announced the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin for Alzheimer's disease at the Alzheimer's Association ...
Primary immunodeficiency (PID) diseases occur in about 1 in every 1200 individuals and are associated with recurrent infections and several comorbidities that contribute to its substantial morbidity ...
NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin (IGIV) for ...
There have been post marketing reports describing serious thrombotic events (vascular occlusion) possibly associated with the administration of ImmuneGlobulin Intravenous (Human) (IGIV). Precautionary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results